Management of venous thrombo-embolism: An update

European Heart Journal

Volumn 35, Issue 41, 2014, Pages 2855-2863

  Konstantinides, Stavros ^a,b   Torbicki, Adam ^c  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^c Center of Postgraduate Medical Education   (Poland)

Author keywords

Anticoagulants; Chronic thrombo embolic pulmonary hypertension; Management; Prognosis; Pulmonary embolism; Risk assessment; Thrombolysis; Venous thrombo embolism

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; AMIODARONE; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; BIOLOGICAL MARKER; CYSTATIN C; CYTOCHROME P450 2C9; D DIMER; DABIGATRAN; EDOXABAN; HEPARIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PHENPROCOUMON; RIVAROXABAN; TICAGRELOR; TROPONIN I; WARFARIN; VITAMIN K GROUP;

AGED; ANEMIA; ANTICOAGULANT THERAPY; ANTICOAGULATION; BARE METAL STENT; BLEEDING; BLOOD PRESSURE; BLOOD TRANSFUSION; BLOOD VESSEL OCCLUSION; CASE REPORT; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; CLINICAL STUDY; COMPRESSION; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONSCIOUSNESS; CORONARY ARTERY OBSTRUCTION; CORONARY CARE UNIT; CREATININE CLEARANCE; DEEP VEIN THROMBOSIS; DISEASE COURSE; DRUG SAFETY; DYSPNEA; ELECTRIC ACTIVITY; EMERGENCY PHYSICIAN; ENDARTERECTOMY; FEMALE; FIBRINOLYTIC THERAPY; GENOTYPE; HEART RATE; HEART RIGHT VENTRICLE PRESSURE; HEMODYNAMICS; HUMAN; INTERMEDIATE RISK POPULATION; INTERNATIONAL NORMALIZED RATIO; KIDNEY FUNCTION; LOADING DRUG DOSE; LUNG EMBOLISM; MONOTHERAPY; OUTPATIENT CARE; PREDICTIVE VALUE; PROSPECTIVE STUDY; REVIEW; RIGHT CORONARY ARTERY; RISK ASSESSMENT; STANDARD; THORAX PAIN; VENOUS THROMBOEMBOLISM; VERY ELDERLY; ALGORITHM; AMBULATORY CARE; ANTAGONISTS AND INHIBITORS; CHRONIC DISEASE; CLINICAL TRIAL (TOPIC); DIAGNOSTIC IMAGING; EARLY DIAGNOSIS; LONG TERM CARE; METABOLISM; ORAL DRUG ADMINISTRATION; PROCEDURES; PULMONARY EMBOLISM;

ADMINISTRATION, ORAL; ALGORITHMS; AMBULATORY CARE; ANTICOAGULANTS; BIOLOGICAL MARKERS; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; DIAGNOSTIC IMAGING; EARLY DIAGNOSIS; HUMANS; LONG-TERM CARE; PULMONARY EMBOLISM; RISK ASSESSMENT; THROMBOLYTIC THERAPY; VENOUS THROMBOEMBOLISM; VITAMIN K;

EID: 84912136814     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehu243     Document Type: Review

References (91)

1. Heit JA. The epidemiology of venous thromboembolism in the community. Arterios-cler Thromb Vasc Biol 2008;28:370-372.
2. Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, Greer IA, Heit JA, Hutchinson JL, Kakkar AK, Mottier D, Oger E, Samama MM, Spannagl M. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007;98:756-764.
3. Biss TT, Brandao LR, Kahr WH, Chan AK, Williams S. Clinical features and outcome of pulmonary embolism in children. Br J Haematol 2008;142:808-818.
4. Stein PD, Kayali F, Olson RE. Incidence of venous thromboembolism in infants and children: data from the National Hospital Discharge Survey. J Pediatr 2004;145: 563-565.
5. Anderson FA Jr, Spencer FA. Risk factors for venous thromboembolism. Circulation 2003;107(23 Suppl 1):I9-16.
6. Torbicki A, Perrier A, Konstantinides SV, Agnelli G, Galie N, Pruszczyk P, Bengel F, Brady AJ, Ferreira D, Janssens U, Klepetko W, Mayer E, Remy-Jardin M, Bassand JP. Guidelines on the diagnosis and management of acute pulmonary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008;29:2276-2315.
7. Gibson NS, Sohne M, Kruip MJ, Tick LW, Gerdes VE, Bossuyt PM, Wells PS, Buller HR. Further validation and simplification of the Wells clinical decision rule in pulmonary embolism. Thromb Haemost 2008;99:229-234.
8. Klok FA, Mos IC, Nijkeuter M, Righini M, Perrier A, Le Gal G, Huisman MV. Simplification of the revised Geneva score for assessing clinical probability of pulmonary embolism. Arch Intern Med 2008;168:2131-2136.
9. Douma RA, Mos IC, Erkens PM, Nizet TA, Durian MF, Hovens MM, van Houten AA, Hofstee HM, Klok FA, ten Cate H, Ullmann EF, Buller HR, Kamphuisen PW, Huisman MV. Performance of 4 clinical decision rules in the diagnostic management of acute pulmonary embolism: a prospective cohort study. Ann Intern Med 2011;154: 709-718.
10. Douma RA, Gibson NS, Gerdes VE, Buller HR, Wells PS, Perrier A, Le Gal G. Validity and clinical utility of the simplified Wells rule for assessing clinical probability for the exclusion of pulmonary embolism. Thromb Haemost 2009;101: 197-200.
11. Righini M, Van EJ, den Exter PL, Roy PM, Verschuren F, Ghuysen A, Rutschmann OT, Sanchez O, Jaffrelot M, Trinh-Duc A, Le GC, Moustafa F, Principe A, van Houten AA, Ten WM, Douma RA, Hazelaar G, Erkens PM, van Kralingen KW, Grootenboers MJ, Durian MF, Cheung YW, Meyer G, Bounameaux H, Huisman MV, Kamphuisen PW, Le GG. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study. JAMA 2014;311:1117-1124.
12. Carrier M, Righini M, Wells PS, Perrier A, Anderson DR, Rodger MA, Pleasance S, Le GG. Subsegmental pulmonary embolism diagnosed by computed tomography: incidence and clinical implications. Asystematic review and meta-analysisofthe management outcome studies. J Thromb Haemost 2010;8:1716-1722.
13. Stein PD, Goodman LR, Hull RD, Dalen JE, Matta F. Diagnosis and management of isolated subsegmental pulmonary embolism: review and assessment of the options. Clin Appl Thromb Hemost 2012;18:20-26.
14. Farrell C, Jones M, Girvin F, Ritchie G, Murchison JT. Unsuspected pulmonary embolism identified using multidetector computed tomography in hospital outpatients. Clin Radiol 2010;65:1-5.
15. Jia CF, Li YX, Yang ZQ, Zhang ZH, Sun XX, Wang ZQ. Prospective evaluation of unsuspected pulmonary embolism on coronary computed tomographic angiography. J Comput Assist Tomogr 2012;36:187-190.
16. Palla A, Rossi G, Falaschi F, Marconi L, Pistolesi M, Prandoni P. Is incidentally detected pulmonary embolism in cancer patients less severe? A case-control study. Cancer Invest 2012;30:131-134.
17. Sahut DM, Caumont PA, Planquette B, Revel MP, Avillach P, Chatellier G, Sanchez O, Meyer G. Risk factors and clinical outcome of unsuspected pulmonary embolism in cancer patients: a case-control study. J Thromb Haemost 2012;10:2032-2038.
18. Jaff MR, McMurtry MS, Archer SL, Cushman M, Goldenberg N, Goldhaber SZ, Jenkins JS, Kline JA, Michaels AD, Thistlethwaite P, Vedantham S, White RJ, Zierler BK. Management of massive and submassive pulmonary embolism, iliofe-moral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation 2011; 123:1788-1830.
19. Aujesky D, Obrosky DS, Stone RA, Auble TE, Perrier A, Cornuz J, Roy PM, Fine MJ. Derivation and validationof aprognostic model for pulmonary embolism. Am JRespir Crit Care Med 2005;172:1041-1046.
20. Aujesky D, Roy PM, Verschuren F, Righini M, Osterwalder J, Egloff M, Renaud B, Verhamme P, Stone RA, Legall C, Sanchez O, Pugh NA, N'gako A, Cornuz J, Hugli O, Beer HJ, Perrier A, Fine MJ, Yealy DM. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: aninternational, open-label, randomised, non-inferiority trial. Lancet 2011;378:41-48.
21. Jimenez D, Aujesky D, Moores L, Gomez V, Lobo JL, Uresandi F, Otero R, Monreal M, Muriel A, Yusen RD. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med 2010;170:1383-1389.
22. Righini M, Roy PM, Meyer G, Verschuren F, Aujesky D, Le GG. The Simplified Pulmonary Embolism Severity Index (PESI): validation of a clinical prognostic model for pulmonary embolism. J Thromb Haemost 2011;9:2115-2117.
23. Lankeit M, Gomez V, Wagner C, Aujesky D, Recio M, Briongos S, Moores LK, Yusen RD, Konstantinides S, Jimenez D. Astrategycombining imaging and laboratory biomarkers in comparison with a simplified clinical score for risk stratification of patients with acute pulmonary embolism. Chest 2012;141:916-922.
24. Kreit JW. The impactofright ventricular dysfunctiononthe prognosis and therapy of normotensive patients with pulmonary embolism. Chest 2004;125:1539-1545.
25. Coutance G, Cauderlier E, Ehtisham J, Hamon M, Hamon M. The prognostic value of markersofright ventricular dysfunction in pulmonary embolism:a meta-analysis. Crit Care 2011;15:R103.
26. Sanchez O, Trinquart L, Colombet I, Durieux P, Huisman MV, Chatellier G, Meyer G. Prognostic value of right ventricular dysfunction in patients with haemodynami-cally stable pulmonary embolism: a systematic review. Eur Heart J 2008;29: 1569-1577.
27. Becattini C, Agnelli G, Vedovati MC, Pruszczyk P, Casazza F, Grifoni S, Salvi A, Bianchi M, Douma R, Konstantinides S, Lankeit M, Duranti M. Multidetector computed tomography for acute pulmonary embolism: diagnosis and risk stratification in a single test. Eur Heart J 2011;32:1657-1663.
28. Becattini C, Agnelli G, Germini F, Vedovati MC. Computed tomography to assess risk of death in acute pulmonary embolism: a meta-analysis. Eur Respir J 2014; [Epub ahead of print].
29. Kucher N, Boekstegers P, Muller OJ, Kupatt C, Beyer-Westendorf J, Heitzer T, Tebbe U, Horstkotte J, Muller R, Blessing E, Greif M, Lange P, Hoffmann RT, Werth S, Barmeyer A, Hartel D, Grunwald H, Empen K, Baumgartner I. Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. Circulation 2014;129:479-486.
30. Meyer G, Vicaut E, Danays T, Agnelli G, Becattini C, Beyer-Westendorf J, Bluhmki E, Bouvaist H, Brenner B, Couturaud F, Dellas C, Empen K, Franca A, Galie N, Geibel A, Goldhaber SZ, Jimenez D, Kozak M, Kupatt C, Kucher N, Lang IM, Lankeit M, Meneveau N, Pacouret G, Palazzini M, Petris A, Pruszczyk P, Rugolotto M, Salvi A, Schellong S, Sebbane M, Sobkowicz B, Stefanovic BS, Thiele H, Torbicki A, Verschuren F, Konstantinides SV. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med 2014;370:1402-1411.
31. Lankeit M, Jimenez D, Kostrubiec M, Dellas C, Kuhnert K, Hasenfuss G, Pruszczyk P, Konstantinides S. Validation of N-terminal pro-brain natriuretic peptide cut-off values for risk stratification of pulmonary embolism. Eur Respir J 2014; [Epub ahead of print].
32. Klok FA, Mos IC, Huisman MV. Brain-type natriuretic peptide levels in the prediction of adverse outcome in patients with pulmonary embolism: a systematic review and meta-analysis. Am J Respir Crit Care Med 2008;178:425-430.
33. Agterof MJ, Schutgens RE, Snijder RJ, Epping G, Peltenburg HG, Posthuma EF, Hardeman JA, van der GR, Koster T, Prins MH, Biesma DH. Out of hospital treatment of acute pulmonary embolism in patients with a low NT-proBNP level. J Thromb Haemost 2010;8:1235-1241.
34. Lankeit M, Jimenez D, Kostrubiec M, Dellas C, Hasenfuss G, Pruszczyk P, Konstantinides S. Predictive value of the high-sensitivity troponin T assay and the simplified pulmonary embolism severity index in hemodynamically stable patients with acute pulmonary embolism: a prospective validation study. Circulation 2011; 124:2716-2724.
35. Dellas C, Tschepe M, Seeber V, Zwiener I, Kuhnert K, Schafer K, Hasenfuss G, Konstantinides S, Lankeit M. A novel H-FABP assay and a fast prognostic score for risk assessment of normotensive pulmonary embolism. Thromb Haemost 2014; 111:996-1003.
36. Lankeit M, Dellas C, Benz V, Hasenfuss G, Konstantinides S. The predictive value of heart-type fatty acid-binding protein is independent from symptom duration in normotensive patients with pulmonary embolism. Thromb Res 2013;132:543-547.
37. Kostrubiec M, Labyk A, Pedowska-Wloszek J, Pacho S, Wojciechowski A, Jankowski K, Ciurzynski M, Pruszczyk P. Assessment of renal dysfunction improves troponin-based short-term prognosis in patients with acute symptomatic pulmonary embolism. J Thromb Haemost 2010;8:651-658.
38. Kostrubiec M, Labyk A, Pedowska-Wloszek J, Dzikowska-Diduch O, Wojciechowski A, Garlinska M, Ciurzynski M, Pruszczyk P. Neutrophil gelatinase-associated lipocalin, cystatin C and eGFR indicate acute kidney injury and predict prognosis of patients with acute pulmonary embolism. Heart 2012;98: 1221-1228.
39. Lankeit M, Friesen D, Schafer K, Hasenfuss G, Konstantinides S, Dellas C. A simple score for rapid risk assessment of non-high-risk pulmonary embolism. Clin Res Cardiol 2013;102:73-80.
40. Agterof MJ, Schutgens RE, Moumli N, Eijkemans MJ, van der Griend R, Tromp EA, Biesma DH. A prognostic model for short term adverse events in normotensive patients with pulmonary embolism. Am J Hematol 2011;86:646-649.
41. Becattini C, Casazza F, Forgione C, Porro F, Fadin BM, Stucchi A, Lignani A, Conte L, Imperadore F, Bongarzoni A, Agnelli G. Acute pulmonary embolism: external validation of an integrated risk stratification model. Chest 2013;144: 1539-1545.
42. Bova C, Sanchez O, Prandoni P, Lankeit M, Konstantinides S, Vanni S, Jimenez D. Identification of intermediate-risk patients with acute symptomatic pulmonary embolism. Eur Respir J 2014; [Epub ahead of print].
43. Jimenez D, Kopecna D, Tapson V, Briese B, Schreiber D, Lobo JL, Monreal M, Aujesky D, Sanchez O, Meyer G, Konstantinides S, Yusen RD. On Behalf Of The Protect Investigators. Derivation and validation of multimarker prognostication for normotensive patients with acute symptomatic pulmonary embolism. Am J Respir Crit Care Med 2014;189:718-726.
44. Konstantinides S, Goldhaber SZ. Pulmonary embolism: risk assessment and management. Eur Heart J 2012;33:3014-3022.
45. Kimmel SE, French B, Kasner SE, Johnson JA, Anderson JL, Gage BF, Rosenberg YD, Eby CS, Madigan RA, McBane RB, Abdel-Rahman SZ, Stevens SM, Yale S, Mohler ER III, Fang MC, Shah V, Horenstein RB, Limdi NA, Muldowney JA III, Gujral J, Delafontaine P, Desnick RJ, Ortel TL, Billett HH, Pendleton RC, Geller NL, Halperin JL, Goldhaber SZ, Caldwell MD, Califf RM, Ellenberg JH. A pharmacoge-netic versus a clinical algorithm for warfarin dosing. N Engl J Med 2013;369: 2283-2293.
46. Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T, Kesteven P, Christersson C, Wahlstrom B, Stafberg C, Zhang JE, Leathart JB, Kohnke H, Maitland-van der Zee AH, Williamson PR, Daly AK, Avery P, Kamali F, Wadelius M. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med 2013;369:2294-2303.
47. Verhoef TI, Ragia G, de BA, Barallon R, Kolovou G, Kolovou V, Konstantinides S, Le CS, Maltezos E, van der Meer FJ, Redekop WK, Remkes M, Rosendaal FR, van Schie RM, Tavridou A, Tziakas D, Wadelius M, Manolopoulos VG, Maitland-van der Zee AH. A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. N Engl J Med 2013;369:2304-2312.
48. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ. Dabigatran versus warfarininthe treatment ofacute venous thromboembolism. N Engl J Med 2009;361:2342-2352.
49. Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, Christiansen AV, Friedman J, Le MF, Peter N, Kearon C. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014;129:764-772.
50. Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S. Oral rivarox-aban for symptomatic venous thromboembolism. N Engl JMed 2010;363:2499-2510.
51. Buller HR, Gallus AS, Pillion G, Prins MH, Raskob GE. Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial. Lancet 2012;379:123-129.
52. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013;369:799-808.
53. Buller HR, Decousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013;369:1406-1415.
54. Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A. Oral rivar-oxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366:1287-1297.
55. Prins MH, Lensing AW, Bauersachs R, van BB, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Raskob GE, Berkowitz SD, Wells PS. Oral riv-aroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 2013;11:21.
56. van Es J, Douma RA, Kamphuisen PW, Gerdes VE, Verhamme P, Wells PS, Bounameaux H, Lensing AW, Buller HR. Clot resolution after 3 weeks of anticoagulant treatment for pulmonary embolism: comparison of computed tomography and perfusion scintigraphy. J Thromb Haemost 2013;11:679-685.
57. Bamber L, Wang MY, Prins MH, Ciniglio C, Bauersachs R, Lensing AW, Cano SJ. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thromb Haemost 2013;110:732-741.
58. van der Hulle T, Kooiman J, den Exter PL, Dekkers OM, Klok FA, Huisman MV. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists inthe treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost 2014;12:320-328.
59. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J 2013;34:2094-2106.
60. Stein PD, Matta F. Thrombolytic therapy in unstable patients with acute pulmonary embolism: saves lives but underused. Am J Med 2012;125:465-470.
61. Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 2002;347:1143-1150.
62. Mikkola KM, Patel SR, Parker JA, Grodstein F, Goldhaber SZ. Increasing age isamajor risk factor for hemorrhagic complications after pulmonary embolism thrombolysis. Am Heart J 1997;134:69-72.
63. Konstantinides S. Clinical practice. Acute Pulmonary Embolism. N Engl J Med 2008; 359:2804-2813.
64. Wang C, Zhai Z, Yang Y, Wu Q, Cheng Z, Liang L, Dai H, Huang K, Lu W, Zhang Z, Cheng X, Shen YH. Efficacy and safety of low dose recombinant tissue-type plas-minogen activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial. Chest 2010;137:254-262.
65. Sharifi M, Bay C, Skrocki L, Rahimi F, Mehdipour M. Moderate pulmonary embolism treated with thrombolysis(from the 'MOPETT' Trial). Am JCardiol 2013;111:273-277.
66. Engelberger RP, Kucher N. Ultrasound-assisted thrombolysis for acute pulmonary embolism: a systematic review. Eur Heart J 2014;35:758-764.
67. Engelberger RP, Kucher N. Catheter-based reperfusion treatmentofpulmonaryem-bolism. Circulation 2011;124:2139-2144.
68. Muriel A, Jimenez D, Aujesky D, Bertoletti L, Decousus H, Laporte S, Mismetti P, Munoz FJ, Yusen R, Monreal M. Survival effects of inferior vena cava filter in patients with acute symptomatic venous thromboembolism and a significant bleeding risk. J Am Coll Cardiol 2014;63:1675-1683.
69. Stein PD, Matta F, Keyes DC, Willyerd GL. Impact of vena cava filters on in-hospital case fatality rate from pulmonary embolism. Am J Med 2012;125:478-484.
70. Zondag W, Kooiman J, Klok FA, Dekkers OM, Huisman MV. Outpatient versus in-patient treatment in patients with pulmonary embolism: a meta-analysis. Eur Respir J 2013;42:134-144.
71. Zondag W, Mos IC, Creemers-Schild D, Hoogerbrugge AD, Dekkers OM, Dolsma J, Eijsvogel M, Faber LM, Hofstee HM, Hovens MM, Jonkers GJ, van Kralingen KW, Kruip MJ, Vlasveld T, DE Vreede MJ, Huisman MV. Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study. J Thromb Haemost 2011;9: 1500-1507.
72. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, Crowther M, Kahn SR. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e419S-e494S.
73. Kyrle PA, Rosendaal FR, Eichinger S. Risk assessment for recurrent venous thrombosis. Lancet 2010;376:2032-2039.
74. Heit JA. Predicting the risk of venous thromboembolism recurrence. Am J Hematol 2012;87(Suppl. 1):S63-S67.
75. Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, Turpie AG, Green D, Ginsberg JS, Wells P, Mac Kinnon B, Julian JA. Acomparison of three months of antic-oagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism [see comments] [published erratum appears in N Engl J Med 1999 Jul 22;341:298]. N Engl J Med 1999;340:901-907.
76. Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, Kvamme AM, Friedman J, Mismetti P, Goldhaber SZ. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013;368:709-718.
77. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Porcari A, Raskob GE, Weitz JI. Apixaban for extended treatment of venous thromboembol-ism. N Engl J Med 2013;368:699-708.
78. Becattini C, Agnelli G, Schenone A, Eichinger S, Bucherini E, Silingardi M, Bianchi M, Moia M, Ageno W, Vandelli MR, Grandone E, Prandoni P. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012; 366:1959-1967.
79. Brighton TA, Eikelboom JW, Mann K, Mister R, Gallus A, Ockelford P, Gibbs H, Hague W, Xavier D, Diaz R, Kirby A, Simes J. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 2012;367:1979-1987.
80. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS, Van Mieghem W, Lip GY, Kim JH, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans AL, Munawar M, O'Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S. Apixabaninpatients with atrial fibrillation. N Engl J Med 2011;364:806-817.
81. Tapson VF, Humbert M. Incidence and prevalence of chronic thromboembolic pulmonary hypertension: from acute to chronic pulmonary embolism. Proc Am Thorac Soc 2006;3:564-567.
82. Lang IM, Pesavento R, Bonderman D, Yuan JX. Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding. Eur Respir J 2013;41:462-468.
83. Klok FA, vanKralingen KW, van Dijk AP, Heyning FH, Vliegen HW, Huisman MV. Pro-spective cardiopulmonary screening program to detect chronic thromboembolic pulmonary hypertension in patients afteracute pulmonary embolism. Haematologica 2010;95:970-975.
84. Pepke-Zaba J, Delcroix M, Lang I, Mayer E, Jansa P, Ambroz D, Treacy C, D'Armini AM, Morsolini M, Snijder R, Bresser P, Torbicki A, Kristensen B, Lewczuk J, Simkova I, Barbera JA, de PM, Hoeper MM, Gaine S, Speich R, Gomez-Sanchez MA, Kovacs G, Hamid AM, Jais X, Simonneau G. Chronicthrombo-embolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation 2011;124:1973-1981.
85. Ghofrani HA, D'Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, Mayer E, Simonneau G, Wilkins MR, Fritsch A, Neuser D, Weimann G, Wang C. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 2013;369:319-329.
86. Darocha S, Kurzyna M, Pietura R, Torbicki A. Balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension. Kardiol Pol 2013;71: 1331.
87. Ishiguro H, Kataoka M, Inami T, Yanagisawa R, Shimura N, Taguchi H, Kohshoh H, Yoshino H, Satoh T. Percutaneous transluminal pulmonary angioplasty for central-type chronic thromboembolic pulmonary hypertension. JACC Cardiovasc Interv 2013;6:1212-1213.
88. Kataoka M, Inami T, Hayashida K, Shimura N, Ishiguro H, Abe T, Tamura Y, Ando M, Fukuda K, Yoshino H, Satoh T. Percutaneous transluminal pulmonary angioplasty for the treatment of chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv 2012;5:756-762.
89. Mizoguchi H, Ogawa A, Munemasa M, Mikouchi H, Ito H, Matsubara H. Refined balloon pulmonary angioplasty for inoperable patients with chronic thromboembol-ic pulmonary hypertension. Circ Cardiovasc Interv 2012;5:748-755.
90. Andreassen AK, Ragnarsson A, Gude E, Geiran O, Andersen R. Balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension. Heart 2013;99:1415-1420.
91. Rubboli A, Halperin JL, Airaksinen KE, Buerke M, Eeckhout E, Freedman SB, Gershlick AH, Schlitt A, Tse HF, Verheugt FW, Lip GY. Antithrombotic therapy in pa-tientstreatedwithoralanticoagulationundergoingcoronaryarterystenting. Anexpert consensus document with focus on atrial fibrillation. Ann Med 2008;40:428-436.